Renal cell carcinoma (RCC) represents 2% of all

Size: px
Start display at page:

Download "Renal cell carcinoma (RCC) represents 2% of all"

Transcription

1 Predictors of Response to Targeted Therapy in Renal Cell Carcinoma Laurie J. Eisengart, MD; Gary R. MacVicar, MD; Ximing J. Yang, MD, PhD N Context. The prognosis for patients with metastatic renal cell carcinoma is poor, with an average 5-year survival of approximately 10%. Use of traditional cytokine therapy, specifically high-dose interleukin 2, is limited by significant toxicity. Better understanding of the molecular pathogenesis of renal cell carcinoma has led to the development of targeted therapies to inhibit specific cellular pathways leading to tumorigenesis. These drugs provide improved survival with a more favorable toxicity profile. There is ongoing investigation of markers that predict response of an individual patient to different targeted therapies. Objective. To explain the molecular basis for vascular endothelial growth factor inhibitor (antiangiogenic) and mammalian target of rapamycin inhibitor therapies for renal cell carcinoma, summarize the clinical trials demonstrating the effectiveness of these drugs, and describe the biomarkers shown to correlate with outcome in patients treated with targeted therapy. Data Sources. All included sources are from peerreviewed journals in PubMed (US National Library of Medicine). Conclusion. Emerging evidence shows promise that biomarkers will be useful for predicting an individual patient s response to targeted therapy, leading to a more personalized approach to treating renal cell carcinoma. (Arch Pathol Lab Med. 2012;136: ; doi: / arpa ra) Renal cell carcinoma (RCC) represents 2% of all malignancies worldwide, and the incidence has risen in the United States in the last 2 decades. 1,2 This increase includes RCC at all stages, suggesting a true rise rather than an artifact of improved imaging for detecting asymptomatic, small tumors. 1 Surgical resection is curative for most patients with localized RCC, but for patients who present with advanced disease or whose disease recurs after surgery, the prognosis is poor. While overall survival rates have improved during the last 6 decades, for patients with metastatic disease, the 5-year survival rate averages 10%. 3 Fortunately, survival may be improved with new therapies for RCC, including molecularly targeted therapies. Traditional cytokine immunotherapy for advanced RCC includes interferon a (IFN-a), low-dose interleukin 2 (IL-2), and high-dose IL-2. In particular, high-dose IL-2 therapy can provoke an immune response against RCC, resulting in lasting, complete remission in approximately 10% of patients. 4 However, use of high-dose IL-2 is limited by its severe toxicity, including hypotension, cardiac arrhythmias, metabolic acidosis, renal failure, neurotoxicity, and dermatologic complications. Patients must receive Accepted for publication July 29, From the Departments of Pathology (Drs Eisengart and Yang) and Medicine, Division of Hematology/Oncology (Dr MacVicar), Northwestern University Feinberg School of Medicine, Chicago, Illinois; and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois (Drs MacVicar and Yang). The authors have no relevant financial interest in the products or companies described in this article. Reprints: Ximing J. Yang, MD, PhD, Feinberg Pavilion 7-338, Surgical Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 251 E Huron St, Chicago, IL ( xyang@northwestern.edu). high-dose IL-2 in a facility that can provide blood pressure support, and only patients with good or intermediate prognosis by Memorial Sloan-Kettering Cancer Center (MSKCC, New York, New York) criteria and excellent organ function are candidates for therapy. 3 As the understanding of the molecular pathogenesis of RCC has improved, new drugs have been developed that target the specific pathways driving tumor growth, specifically, vascular endothelial growth factor (VEGF) driven angiogenesis and the mammalian target of rapamycin (mtor) pathways. Clinical trials have shown that these targeted therapies are effective at improving survival and have a more favorable toxicity profile than traditional cytokine therapy These trials provide some guidance as to which therapy may be most appropriate in a given clinical situation, but discovery and validation of biomarkers that can predict an individual patient s response to a given therapy is an area of active investigation, and many of these predictors are still in the research and investigation phase. However, some trials have shown that the histologic subtype and morphologic features of renal cell carcinoma can be important predictors of response to targeted therapy. This article will discuss the molecular basis of targeted therapies, summarize the clinical trials demonstrating their effectiveness, and review the predictors of response, including histologic and immunohistochemical features that can be used by the practicing pathologist and those that are currently in the investigative phase. VEGF PATHWAY INHIBITORS (ANTIANGIOGENIC AGENTS) Molecular Basis The von Hippel-Lindau (VHL) syndrome is an autosomal dominant disorder characterized by loss of the VHL 490 Arch Pathol Lab Med Vol 136, May 2012 Response to Targeted Agents for Kidney Cancer Eisengart et al

2 tumor suppressor gene located on chromosome 3p25. Clinical manifestations include central nervous system hemangioblastomas, retinal angiomas, and solid tumors, including clear cell RCC. In VHL syndrome, a second hit results in the loss of both copies of the VHL gene in a given cell and leads to tumorigenesis. In sporadic clear cell RCC, biallelic VHL gene loss through either deletion of the short arm of chromosome 3 (3p) or promoter hypermethylation is observed in 70% to 80% of cases. 16,17 The VHL gene encodes a 213 amino acid protein (pvhl) that functions as the substrate recognition component of a ubiquitin ligase targeting the transcription factor hypoxia-inducible factor (HIF) for degradation in the presence of oxygen. 18,19 pvhl recognizes the a subunits HIF-1a and HIF-2a. 19 In hypoxic conditions, or when VHL is lost, HIF is not degraded and travels to the nucleus where it induces transcription of genes to restore normoxia. 19 Of the proteins transcribed, the most important in terms of tumor angiogenesis is VEGF, a member of the platelet-derived growth factor family. Vascular endothelial growth factor binds transmembrane receptors with protein kinase activity that activate cellular pathways to induce proangiogenic changes. 19,20 Targeted Therapies Two approaches have been developed to target the VEGF pathway. The first is the use of small-molecule tyrosine kinase inhibitors such as sunitinib or sorafenib to block the intracellular protein kinase activity of the VEGF receptor. The second is a monoclonal antibody (bevacizumab) that binds circulating VEGF and prevents its binding to and activation of the receptor. Sunitinib. Sunitinib is a tyrosine kinase inhibitor that blocks the VEGF receptor, as well as platelet-derived growth factor receptor, FLT-3, and c-kit. 21 Efficacy of sunitinib was demonstrated in 2 phase II trials of patients with metastatic RCC whose disease had progressed during cytokine therapy, with response rates of 34% to 40% and a median time to progression of 8 months. 13,14 Compared with IFN-a in a phase III trial, sunitinib had an increased response rate (39% versus 8%) and prolonged progression-free survival (PFS) (11 versus 5 months) and overall survival (OS) (26.4 versus 21.8 months). 11,12 As a result, sunitinib is often selected as first-line treatment for patients with advanced RCC, particularly when immunotherapy is not a consideration. Sorafenib. Sorafenib is a tyrosine kinase inhibitor that blocks the VEGF receptor, as well as FLT-3, c-kit, plateletderived growth factor receptor, fibroblast growth factor receptor, C-raf, and B-raf. 22 The phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET), comparing sorafenib to placebo in patients for whom prior cytokine therapy had failed, showed improved OS for sorafenib when excluding those patients who received sorafenib only after the disease had progressed with placebo. 6 A phase II trial comparing sorafenib to IFN-a as first-line therapy showed greater tumor shrinkage and quality of life for patients receiving sorafenib, but no increase in PFS. Sorafenib dose escalation after disease progression was well tolerated and led to an additional 4 months of PFS. 8 Bevacizumab. Bevacizumab is a monoclonal antibody that binds and neutralizes all circulating isoforms of VEGF with high affinity. 23 A phase II trial of patients with disease progression after cytokine therapy showed a significant increase in PFS for high-dose bevacizumab compared to placebo, but no difference in OS. 15 The phase III AVOREN trial compared bevacizumab plus IFN-a to IFN-a alone as first-line therapy for patients with metastatic RCC. Bevacizumab plus IFN-a produced significantly increased PFS (10.2 versus 5.5 months) and response rate (31% versus 13%), 7 and final analysis showed a nonsignificant trend toward improved survival (23.3 versus 21.3 months). 24 The authors 24 note that poststudy treatment of patients with tyrosine kinase inhibitors had most likely increased their survival, especially for those who had received placebo on trial, confounding the OS results. Predictors of Response Clinical Features. In the drug trials, some pretreatment clinical features have had a statistically significant relationship to outcome in patients treated with VEGF inhibitors. In the phase II trial of sunitinib for patients with unsuccessful cytokine therapy, longer progression freesurvival was observed for patients with normal serum hemoglobin (than those with baseline hemoglobin below the lower limit of normal), with favorable Eastern Cooperative Oncology Group (ECOG) performance status, lack of liver metastasis, and fewer disease sites (0 or 1 versus 2 or more). A trend toward improved OS (P 5.06) was seen for alkaline phosphatase levels lower than 120 U/L. 14 In the phase III trial of sunitinib as first-line therapy, improved OS was seen for patients with favorable ECOG performance status, normal hemoglobin levels, time from diagnosis to treatment of more than 1 year, corrected calcium levels lower than 10 mg/dl, lactate dehydrogenase (LDH) levels less than 1.5 times the upper limit of normal, alkaline phosphatase levels below the upper limit of normal, and 1 (versus 2 or more) metastatic site. 11,12 In the phase III TARGET trial of sorafenib, ECOG performance status and MSKCC score were independent prognostic factors for PFS and OS. In addition, patients older than 70 years had significantly improved PFS without increased toxicity. 25 A study of 120 patients with metastatic clear cell RCC treated with any VEGF inhibitor (sunitinib, sorafenib, or bevacizumab) found 5 independent clinical prognostic factors associated with shorter PFS: time from diagnosis to treatment of less than 2 years, platelet count greater than /ml, neutrophil count greater than /ml, corrected serum calcium levels below 8.5 mg/dl or above 10 mg/dl, and ECOG performance status score greater than Histology. While most studies have included only patients with clear cell histology, there are data to suggest that the subtype of RCC is a useful predictor of response to therapy. In particular, papillary or chromophobe RCC subtype may predict superior response to sunitinib over sorafenib. In a retrospective review of 53 patients with papillary or chromophobe RCC treated with sunitinib or sorafenib, there was an overall response rate of 10%, PFS of 8.6 months, and OS of 19.6 months. Progression-free survival was significantly longer for patients treated with sunitinib than sorafenib (11.9 versus 5.1 months). 27 Data also suggest that evaluation of specific histologic features in clear cell RCC may be helpful in predicting response to VEGF pathway inhibitors. A number of histologic features, including Fuhrman grade, growth pattern, degree of clear cytology versus eosinophilia, and Arch Pathol Lab Med Vol 136, May 2012 Response to Targeted Agents for Kidney Cancer Eisengart et al 491

3 presence of rhabdoid and sarcomatoid features, were evaluated in patients with metastatic clear cell RCC receiving first-line VEGF inhibitor therapy. 28 Multivariate modeling showed that greater tumor shrinkage was associated with a higher clear cell component (P 5.02), presence of rhabdoid features (P 5.06), and light eosinophilic cytology of 50% or less (P 5.05). Greater clear cell component was also associated with partial treatment response (P 5.02) and longer treatment duration (P 5.02) but not OS (P 5.57). A retrospective analysis of 43 patients with metastatic clear cell RCC with sarcomatoid features, treated with VEGF-targeted therapy, compared outcomes by underlying RCC subtype and by percentage of sarcomatoid histology. 29 The overall objective partial response rate was 19%; stable disease was the outcome in 49% of cases and progressive disease was the best response in 33%. In regard to RCC subtype, partial response was only achieved in patients with underlying clear cell RCC. Of these patients, 61% had tumor shrinkage, and they had a median PFS of 6 months and OS of 13.1 months. Of those with papillary, chromophobe, or unclassified RCC, only 30% had any tumor shrinkage. Because of the small sample size of patients with non clear cell histology, there were no statistically significant differences in survival outcomes. A larger proportion of sarcomatoid elements negatively affected response: partial response was only achieved in those with less than 20% sarcomatoid elements (P 5.02). Those with less than 20% sarcomatoid elements showed greater tumor reduction (P 5.05), and PFS and OS favored these patients but was not statistically significant. Those with non clear cell histology had a higher percentage of sarcomatoid elements on average. To clarify the effect of the presence of sarcomatoid elements, the patients with underlying clear cell RCC were matched for age, sex, treatment, and prognostic risk group with patients who had clear cell RCC but no sarcomatoid elements. Those without sarcomatoid elements had longer PFS (P,.001), greater tumor shrinkage (P 5.005), and a greater response rate to therapy (P 5.02). Overall, clear cell RCC may be associated with a better response to VEGF-targeted therapy, but papillary and chromophobe RCC may show a better response to sunitinib than to sorafenib. Sarcomatoid elements are a negative predictor of response. Immunohistochemistry: Carbonic Anhydrase IX Expression. Carbonic anhydrase IX (CAIX) is a transmembrane protein involved in cell proliferation that is upregulated by HIF and is expressed in most clear cell RCCs. 30 Carbonic anhydrase IX expression by immunohistochemistry was evaluated in tumors from 118 patients receiving first-line VEGF inhibitor therapy with either sunitinib or sorafenib. 28 Level of immunohistochemical expression of CAIX was not predictive of OS. However, high CAIX expression, defined as greater than 85% of tumor cells positive for the marker, was associated with a better response rate in the patients treated with sorafenib, suggesting CAIX expression may be a predictive marker for sorafenib. VEGF Levels. Blood levels of VEGF have been shown to be prognostic for patients receiving VEGF tyrosine kinase inhibitors. In a study of 63 patients with metastatic RCC for whom cytokine therapy was unsuccessful, levels of VEGF and of the soluble VEGF receptors svegfr-2 and svegf-3 were monitored during treatment with sunitinib. Levels of VEGF increased in 44% of patients, while svegfr-2 and svegfr-3 levels decreased in 91% and 87% of patients, respectively. For those with measurable changes in these 3 proteins, significantly larger changes compared to baseline were observed for patients showing objective tumor response than for those with stable disease or disease progression. 31 Additionally, the phase III TARGET trial of sorafenib prospectively studied VEGF levels and found that patients with higher baseline ECOG performance status or MSKCC score both predictors of poor prognosis had significantly higher baseline levels of VEGF. Further, higher baseline levels of VEGF were associated with decreased PFS and OS for patients receiving placebo and with decreased OS for patients treated with sorafenib. The data also suggested that while all patients benefitted from sorafenib, patients with high baseline VEGF levels derived more benefit from sorafenib than those with low levels. 6 In contrast, the phase II trial of bevacizumab did not find any association between detectable pretreatment VEGF levels and clinical response or time to progression. The authors 15 note that the limited sensitivity of their VEGF assay prevents making a definitive conclusion. VHL Gene Mutation Status. The type of VHL mutation in RCC may predict response to VEGF targeted therapy. In a study of 123 patients with metastatic clear cell RCC treated with VEGF inhibitors, patients with VHL inactivation did not have a significantly different response rate than those with wild-type VHL. However, loss-offunction mutations of VHL (frameshift, nonsense, splice and in-frame deletions/insertions) were an independent prognostic factor for improved response versus wild-type VHL. 32 Another study of 43 patients treated with VEGF inhibitors found that VHL mutation status did not affect objective response, but those patients with VHL methylation or with mutations that caused truncation or frameshift mutations appeared to have longer time to tumor progression. 33 Cell Cycle and Proliferation Markers. Gene and protein expression of cell cycle and proliferation markers in posttherapy nephrectomy specimens, assayed with reverse-phase protein array and gene expression microarray, were predictive for PFS and OS in a study of 38 patients treated with bevacizumab. 34 High protein level of AMPK, a tumor suppressor that inhibits the proliferation effects of the phosphoinositide 3 kinase (PI3K)/Akt pathway, was associated with longer PFS and OS. Increased protein expression of PTEN, another tumor suppressor of the PI3K/Akt pathway, correlated with a longer OS. In contrast, increased expression of phosphorylated Akt (pakt) and its downstream product, phospho-s6 (ps6), was associated with shorter OS. Additionally, high protein level of cyclin B1, which promotes mitosis, was associated with shorter PFS and OS. With gene expression microarray, down-regulation of genes in the PI3K pathway and genes involved in cell cycle control were correlated with longer PFS. Radiologic Imaging. Contrast-enhanced imaging of tumors, which can assess tumor microvascularity, has been shown to be predictive of response to antiangiogenic therapy. Contrast-enhanced computed tomography of metastatic lesions in patients treated with tyrosine kinase VEGF inhibitors showed that tumor enhancement and enhancement pattern were predictive of objective response, and tumor enhancement was associated with 492 Arch Pathol Lab Med Vol 136, May 2012 Response to Targeted Agents for Kidney Cancer Eisengart et al

4 tumor size reduction, time to size reduction, and PFS. 35 A study of dynamic contrast-enhanced magnetic resonance imaging (MRI) of metastases in patients treated with sorafenib showed that those with a high baseline parameter of volume transfer constant of contrast agent had better PFS. 36 A study currently ongoing at our institution compares diffusion-weighted MRI of primary renal cell carcinomas and abdominal metastases pre- and post-neoadjuvant treatment with sorafenib. Following surgical resection, MRI changes will be correlated with histologic parameters including tumor necrosis. mtor PATHWAY INHIBITORS Molecular Basis Mammalian target of rapamycin, an intracellular serine/ threonine kinase upregulated in many human cancers, is downstream of the PI3K/Akt pathway regulated by the PTEN tumor suppressor gene. 19,37 When activated, mtor phosphorylates protranslation factors and induces translation of messenger RNAs encoding cell cycle regulators that promote proliferation, as well as the messenger RNA for HIF. Targeted Therapies Temsirolimus. Temsirolimus is a parenterally administered rapamycin analog that inhibits the mtor kinase via competitive inhibition. 38 In a phase II trial of patients who had undergone unsuccessful cytokine therapy, or who were not candidates for cytokine therapy, various doses of temsirolimus were investigated. 5 While response rate was low (7%), antitumor activity was shown by the significant fraction of patients with minor responses (26%) and/or stable disease for 6 months or more (17%), and the long time to progression (5.8 months) and median OS of 15 months. 5 A phase III trial of temsirolimus as first-line therapy in poor-prognosis patients compared temsirolimus alone, temsirolimus plus IFN-a, and IFN-a alone. Temsirolimus alone compared to IFN-a alone showed significantly increased OS (10.9 versus 7.3 months) and PFS (3.8 versus 1.9 months or 5.5 versus 3.1 months by site investigator or independent radiologist, respectively). Temsirolimus plus IFN-a was not better than IFN-a alone. As IFN-a alone showed no effect, temsirolimus alone and temsirolimus plus IFN-a were expected to be equivalent. The lack of effect in the temsirolimus plus IFN-a treatment arm may be due to dose reductions of temsirolimus in the combination, necessary because of toxicity. 9 Everolimus. Everolimusisanoralcompetitiveinhibitor of mtor. 38 A phase III trial investigated everolimus in patients whose disease had progressed while taking or within 6 months of stopping treatment with VEGF tyrosine kinase inhibitors; some patients had also received previous VEGF antibodies or cytokine therapy. 10 Compared to placebo, everolimus showed significantly increased PFS (4.0 versus 1.9 months) and stable disease was more common (63% versus 32%). There was no significant difference in OS, but patients were allowed to cross over from placebo to everolimus upon disease progression. 10 Therefore, everolimus is the only agent with phase III data supporting its use in the setting of failed VEGF inhibitor therapy. Predictors of Response Clinical Features. Some clinical features are associated with improved outcomes in patients treated with mtor inhibitors. In the phase III trial of temsirolimus, improved OS was observed for patients younger than 65 years, with Karnofsky performance status score below 70, and with LDH levels more than 1.5 times the upper limit of normal. 9 The phase II trial of temsirolimus found that patients stratified to intermediate and poor prognosis by the clinical criteria for prediction of response to IFN-a had the most benefit from temsirolimus. 5 Histology. As most clinical trials have included only patients with clear cell RCC, or have not specified RCC subtype in their patients, there are limited data available on the effect of RCC subtype and histology on response to mtor pathway inhibitors. However, a subset analysis of the phase III trial of temsirolimus looked at the influence of tumor histology on response to the drug. 39 Most patients included in the trial had clear cell RCC (81%), while 13% of tumors were classified as indeterminate and 6% as non clear cell; of the patients with non clear cell tumor for which the subtype was known, 75% had papillary RCC. For patients with clear cell tumors, median OS and PFS were longer for temsirolimus than IFN, with hazard ratios of 0.82 and 0.76, respectively. For patients with other tumor histologic profiles, median OS and PFS also were longer for temsirolimus, with hazard ratios of 0.49 and 0.38, respectively. These data suggest a good response to temsirolimus even in non clear cell RCC. mtor Pathway Molecule Expression. The levels of mtor pathway products in tissue may predict prognosis. A study using tissue microarrays of primary RCCs, metastatic RCCs, and normal kidney found that levels of phosphorylated mtor, pakt, and p-p70s6k, a downstream mtor signaler, were overexpressed in RCC by both Western blot analysis and immunohistochemistry. 40 An immunohistochemical study using tissue microarrays of nephrectomy specimens evaluated pakt, PTEN, ps6, and p27, a downstream mtor product, and related these to prognosis. 39 High nuclear pakt levels were associated with favorable prognosis, while high cytoplasmic pakt levels were associated with poor prognosis. Expression of both cytoplasmic and nuclear pakt, PTEN, ps6, and cytoplasmic p27 were all predictors of disease-specific survival. In this study, information regarding adjuvant therapy was not available. In another study of patients treated with temsirolimus, immunohistochemical overexpression of ps6 and pakt was associated with response to treatment, and no patient without high ps6 or pakt expression experienced an objective tumor response. 41 However, in this analysis, immunohistochemical expression of CAIX did not correlate with tumor response. 41 Another study 42 used immunohistochemistry to evaluate baseline PTEN and HIF-1a expression in pretreatment tumor specimens and subsequent response to temsirolimus, and found no correlation with PFS or OS. VHL Gene Mutation Status. VHL mutation status was evaluated in patients treated with temsirolimus and was not found to correlate with response to therapy. 41 HIF Subunit Expression. The 2 types of HIF subunits recognized by pvhl, HIF-1a, and HIF-2a show overlapping but distinct characteristics. 43 HIF-1a plays an important role in activation of genes involved in glucose metabolism and inhibits the oncoprotein c-myc. HIF-2a stimulates expression of the stem cell marker Oct-4 and promotes c-myc mediated cell cycle progression. HIF-1a remains susceptible to degradation in the absence of pvhl, whereas HIF-2a does not. 44 Importantly, HIF-1a Arch Pathol Lab Med Vol 136, May 2012 Response to Targeted Agents for Kidney Cancer Eisengart et al 493

5 synthesis is more sensitive to mtor inhibitors than is HIF-2a. 45 In a study of 160 clear cell RCCs with VHL inactivation, gene expression microarray found 2 subsets of tumors: those that expressed both HIF-1a and HIF-2a (H1H2), and those that expressed only HIF-2a (H2). 43 The H1H2 tumors showed increased Akt/mTOR activation, while H2 tumors showed increased c-myc expression. 43 These findings suggest possible differences in susceptibility to treatment for H1H2 versus H2 tumors, and future studies will be valuable for correlation with clinical outcomes. ROLE OF THE PATHOLOGIST Precise diagnosis of renal tumors is important in selection of therapy, whether traditional or targeted. While most clinical trials have targeted clear cell RCC, accurate subclassification is important, as some other subtypes have been shown to respond to particular therapies, and for use in future studies of the efficacy of these and other therapies for each subtype of RCC. The World Health Organization classification of renal tumors divides renal epithelial tumors into conventional (clear cell) RCC, papillary RCC, chromophobe RCC, as well as the benign lesion oncocytoma, and other more rare carcinomas. 46 When the morphology is classic, classification of a given tumor can be straightforward. However, renal tumors often do not adhere to classic morphology. Histologic heterogeneity within a lesion is common, including not only variable nuclear grade but also architectural and cytologic features including degree of cytoplasmic eosinophilia. Further, there can be significant overlap in histologic features among these lesions. In a given area of a renal tumor, the differential diagnosis based on morphology can be broad and include both benign and malignant lesions. Familiarity with and judicious use of a basic panel of immunohistochemical stains can clarify the diagnosis in most cases. For example, a panel might include carbonic anhydrase 9 for clear cell RCC, 30 a-methylacyl-coa racemase for papillary RCC, 47 cytokeratin 7 for papillary RCC and chromophobe RCC, 30,39 50 and c-kit for chromophobe RCC and oncocytoma. 51,52 Morphology and immunohistochemistry will resolve the subtype in most RCCs encountered in practice, but newer molecular techniques are also available to aid in subtyping difficult tumors. Gene expression profiles have been able to resolve renal tumors into subtypes that correspond with the histologic classification This technique, which uses clustering analysis to group tumors based on gene expression in complementary DNA microarrays, not only allows a molecular classification of renal tumors but also identifies candidate immunohistochemical markers when a particular gene is uniquely overexpressed in a given tumor subtype The gene expression profile alone may also serve as a predictive marker for outcome in RCC. 57 Accurate classification of tumors will be of increasing importance as more targeted therapies are developed, so that the therapy most effective in a given tumor subtype can be administered for each patient. CONCLUSION As the understanding of the molecular biology of RCC has advanced, therapies targeted to specific pathways of tumorigenesis have offered improved survival, with less toxicity than traditional cytokine therapy, to patients with advanced RCC. Discovery of biomarkers predictive of an individual patient s response to a given targeted therapy is an area of active investigation that promises to better personalize cancer treatment in the future. It is important to note that renal cell carcinoma is composed of a wide spectrum of subtypes based on their morphologic, biochemical, and molecular genetic background. 53,54 Their responses to a specific therapy could be widely different because of their molecular variability. Most current therapies are targeting only the most common type of RCC, clear cell type. 58 The therapeutic experience with other subtypes of RCC, such as papillary RCC, is limited. 27,54,59 In the future, the stratification of subtypes of RCC and evaluation of responses of patients with different subtypes of RCC to targeted therapies will be critical for success of the targeted therapy. References 1. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176(6, pt 1): McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol. 2006;33(5): Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8): Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer ( ): a benchmark for emerging targeted cancer therapies. Cancer. 2008;113(9): Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5): Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol. 2009;27(20): Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet. 2007;370(9605): Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of firstline treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(8): Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22): Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637): Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22): Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2): Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1): Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21): Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5): Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994; 91(21): Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994;54(11): Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2(9): Suarez C, Morales R, Munoz E, Rodon J, Valverde CM, Carles J. Molecular basis for the treatment of renal cell carcinoma. Clin Transl Oncol. 2010;12(1): Breen EC. VEGF in biological control. J Cell Biochem. 2007;102(6): Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res. 2003;9(1): Wilhelm SM, Carter C, Tang L, et al. BAY exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and 494 Arch Pathol Lab Med Vol 136, May 2012 Response to Targeted Agents for Kidney Cancer Eisengart et al

6 receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19): Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-vegf antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5): Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13): Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008; 100(20): Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110(3): Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1): Choueiri TK, Regan MM, Rosenberg JE, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clearcell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106(6): Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2): Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997;57(14): Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007; 5(7): Choueiri TK, Vaziri SA, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma [discussion in J Urol. 2008;180(3): ]. J Urol. 2008;180(3): Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006;98(4): Tsavachidou-Fenner D, Tannir N, Tamboli P, et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol. 2010;21(8): Han KS, Jung DC, Choi HJ, et al. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer. 2010;116(10): Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26(28): Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mtor pathway. Curr Opin Cell Biol. 2005;17(6): Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs. 2002; 3(2): Dutcher J, Szczylik C, Tannir R, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients wtih advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) [abstract]. J Clin Oncol. 2007;25:243s. 40. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpressed and activated mtor pathway in renal cell carcinomas. Ann Clin Lab Sci. 2006;36(3): Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007;5(6): Figlin RA, de Souza P, McDermott D, et al. Analysis of PTEN and HIF- 1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer. 2009; 115(16): Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008;14(6): Kaelin WG Jr. Kidney cancer: now available in a new flavor. Cancer Cell. 2008;14(6): Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mtorc1 and mtorc2. J Biol Chem. 2008;283(50): Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; World Health Organization Classification of Tumours; vol Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alphamethylacyl-coa racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28(1): Adley BP, Papavero V, Sugimura J, et al. Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Anal Quant Cytol Histol. 2006;28(4): Memeo L, Jhang J, Assaad AM, et al. Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol. 2007;127(2): Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29(6): Huo L, Sugimura J, Tretiakova MS, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol. 2005;36(3): Petit A, Castillo M, Santos M, et al. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol. 2004;28(5): Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003; 22(43): Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005;65(13): Schuetz AN, Yin-Goen Q, Amin MB, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn. 2005;7(2): Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158(5): Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer. 2010;1(2): Meeks JJ, Kasper KA, Yang X, Kuzel TM, Smith ND. Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor. Urology. 2009;73(2):444.e e12. doi: / j.urology Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomeraseinhibiting therapy. BJU Int. 2010;106(1): Arch Pathol Lab Med Vol 136, May 2012 Response to Targeted Agents for Kidney Cancer Eisengart et al 495

Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?

Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used? european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will

More information

Sequential Therapy in Renal Cell Carcinoma*

Sequential Therapy in Renal Cell Carcinoma* Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment

More information

Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma

Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma JOURNAL OF CASE REPORTS 2015;5(1):280-284 Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma Chanchal Goswami, Aditi Mandal B. P. Poddar Hospital & Medical Research

More information

Evidenze cliniche nel trattamento del RCC

Evidenze cliniche nel trattamento del RCC Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,

More information

Metastatic renal cancer (mrcc): Evidence-based treatment

Metastatic renal cancer (mrcc): Evidence-based treatment Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:

More information

Targeted and immunotherapy in RCC

Targeted and immunotherapy in RCC Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted

More information

Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?

Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?

More information

Targeted Therapy in Advanced Renal Cell Carcinoma

Targeted Therapy in Advanced Renal Cell Carcinoma Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio

More information

David N. Robinson, MD

David N. Robinson, MD David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell

More information

Sorafenib in the management of metastatic renal cell carcinoma

Sorafenib in the management of metastatic renal cell carcinoma SORAFENIB IN THE MANAGEMENT OF METASTATIC RCC UROLOGIC ONCOLOGY Sorafenib in the management of metastatic renal cell carcinoma C. Guevremont b s c, C. Jeldres m d, P. Perrotte m d, and P.I. Karakiewicz

More information

Axitinib in renal cell carcinoma: now what do we do?

Axitinib in renal cell carcinoma: now what do we do? Renal Cell Carcinoma Axitinib in renal cell carcinoma: now what do we do? Ian D. Davis Monash University Eastern Health Clinical School, Level 2, Box Hill, Victoria 3128, Australia Correspondence to: Ian

More information

Medical Management of Renal Cell Carcinoma

Medical Management of Renal Cell Carcinoma Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,

More information

Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt

Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt DOI:http://dx.doi.org/10.7314/APJCP.2015.16.5.1971 Efficacy and Toxicity of Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma RESEARCH ARTICLE Efficacy and Toxicity of Sunitinib in Metastatic

More information

Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease

Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2013;45(4):349-353 Case Report http://dx.doi.org/10.4143/crt.2013.45.4.349 Open Access Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients

More information

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma Xu and Wu Biomarker Research (2015) 3:5 DOI 10.1186/s40364-015-0030-7 REVIEW Open Access Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma Kevin Y Xu 1 and Shenhong

More information

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE

More information

Targeted Therapy for Metastatic Renal Cell Carcinoma Robert J. Motzer and Ronald M. Bukowski

Targeted Therapy for Metastatic Renal Cell Carcinoma Robert J. Motzer and Ronald M. Bukowski VOLUME 24 NUMBER 35 DECEMBER 10 2006 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Targeted Therapy for Metastatic Renal Cell Carcinoma Robert J. Motzer and Ronald M. Bukowski From the Genitourinary

More information

Angiogenesis Targeted Therapies in Renal Cell Carcinoma

Angiogenesis Targeted Therapies in Renal Cell Carcinoma Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T

More information

Fifteenth International Kidney Cancer Symposium

Fifteenth International Kidney Cancer Symposium The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

Current Status of Studies on Targeted Therapy for Renal Cell Carcinoma

Current Status of Studies on Targeted Therapy for Renal Cell Carcinoma 294 Chin J Clin Oncol (2008) 5: 294~298 DOI 10.1007/s11805-008-0294-x Current Status of Studies on Targeted Therapy for Renal Cell Carcinoma Shaoqi Wang 1 Shaoxiang Wang 2 Juan Wang 1 1 Department of Oncology,

More information

Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents

Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology

More information

CLINICAL INVESTIGATION of new agents and combination

CLINICAL INVESTIGATION of new agents and combination Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma By Robert J. Motzer, Jennifer Bacik, Barbara A. Murphy, Paul Russo, and Madhu Mazumdar

More information

Characterization of Patients with Poor-

Characterization of Patients with Poor- Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,

More information

A Review in the Treatment Options for Renal Cell Cancer

A Review in the Treatment Options for Renal Cell Cancer A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL

More information

Renal Cell Carcinoma: Genetics & Imaging Srinivasa R Prasad University of Texas San Antonio

Renal Cell Carcinoma: Genetics & Imaging Srinivasa R Prasad University of Texas San Antonio Renal Cell Carcinoma: Genetics & Imaging Srinivasa R Prasad University of Texas HSC @ San Antonio No financial disclosures Acknowledgements Dr. Peter Choyke, NIH My Gurus @ MIR, MGH 2004 WHO Taxonomy of

More information

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies British Journal of Cancer (2011) 105, 1635 1639 All rights reserved 0007 0920/11 www.bjcancer.com Short Communication Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted

More information

Renal cell cancer: overview and immunochemotherapy

Renal cell cancer: overview and immunochemotherapy 1 Renal cell cancer: overview and immunochemotherapy Vincent Khoo Introduction and epidemiology Kidney cancer is a relatively common urological cancer, accounting for approximately 2% of all adult cancers.

More information

Continued Progress in the Treatment of Advanced Renal Cell Carcinoma: An Update on the Role of Sunitinib

Continued Progress in the Treatment of Advanced Renal Cell Carcinoma: An Update on the Role of Sunitinib european urology supplements 7 (2008) 579 584 available at www.sciencedirect.com journal homepage: www.europeanurology.com Continued Progress in the Treatment of Advanced Renal Cell Carcinoma: An Update

More information

I Kid(ney) You Not: Updates on Renal Cell Carcinoma

I Kid(ney) You Not: Updates on Renal Cell Carcinoma Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives

More information

The Therapeutic Landscape in Advanced Renal Cell Carcinoma

The Therapeutic Landscape in Advanced Renal Cell Carcinoma The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in

More information

european urology 53 (2008)

european urology 53 (2008) european urology 53 (2008) 376 381 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients

More information

Introduction. pissn , eissn Cancer Res Treat. 2014;46(4):

Introduction. pissn , eissn Cancer Res Treat. 2014;46(4): pissn 1598-2998, eissn 2005-9256 Original Article http://dx.doi.org/10.4143/crt.2013.154 Open Access Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following

More information

Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis

Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 2275-2280, 2015 Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis QINXIANG TAN 1*,

More information

Metastatic Renal Cancer Medical Treatment

Metastatic Renal Cancer Medical Treatment Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities

More information

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1 Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013

More information

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer

More information

Timing of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital

Timing of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases

More information

Oncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ

Oncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ Oncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ Axel Bex, Christian Blank, Wim Meinhardt, Harm van Tinteren, Simon

More information

State-of-the-art treatment of metastatic renal cell carcinoma

State-of-the-art treatment of metastatic renal cell carcinoma HENG and KOLLMANNSBERGER UROLOGIC ONCOLOGY State-of-the-art treatment of metastatic renal cell carcinoma D.Y.C. Heng m d* and C. Kollmannsberger m d ABSTRACT Targeted therapy has greatly changed the way

More information

Positioning Antiangiogenesis Drugs and Other Agents in Renal Cell Cancer Treatment

Positioning Antiangiogenesis Drugs and Other Agents in Renal Cell Cancer Treatment Positioning Antiangiogenesis Drugs and Other Agents in Renal Cell Cancer Treatment Ahmad Awada, MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) Brussels, Belgium

More information

Ito et al. BMC Cancer 2012, 12:337

Ito et al. BMC Cancer 2012, 12:337 Ito et al. BMC Cancer 212, 12:337 RESEARCH ARTICLE Open Access C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from

More information

The Met Pathway as a Target in RCC

The Met Pathway as a Target in RCC The Met Pathway as a Target in RCC Harriet Kluger, M.D. Associate Professor Yale Cancer Center Disclosures pertinent to this presentation - none c-met Pathway (Biocarta) Rationale for c-met targeting in

More information

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016221.1045 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 1 PROGNOSTIC FACTORS

More information

Innovaciones en el tratamiento del ca ncer renal. Enrique Grande

Innovaciones en el tratamiento del ca ncer renal. Enrique Grande Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc

More information

UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA

UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation

More information

Cytoreductive Nephrectomy

Cytoreductive Nephrectomy Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016

pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report

More information

CLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12

CLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12 Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis

Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis Perspective Page 1 of 5 Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis Parth K. Modi 1, Eric A. Singer 1,2 1 Division of Urology, Rutgers Robert Wood Johnson

More information

The PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction

The PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have

More information

Brain Metastasis in a Patient with a Sarcomatoid Variant RCC with Well-controlled Extracerebral Metastases by Temsirolimus

Brain Metastasis in a Patient with a Sarcomatoid Variant RCC with Well-controlled Extracerebral Metastases by Temsirolimus Brain Metastasis in a Patient with a Sarcomatoid Variant RCC with Well-controlled Extracerebral Metastases by Temsirolimus NOBUYUKI KIKUNO 1, TAKAFUMI KENNOKI 1, HIRONORI FUKUDA 1, YUICHI MATSUMOTO 1,

More information

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better?

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial

More information

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology

More information

pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma

pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr

More information

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D. Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed

More information

Renal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation

Renal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches

More information

Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis

Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A

More information

Linee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona

Linee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical

More information

Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports

Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports european urology supplements 7 (2008) 610 614 available at www.sciencedirect.com journal homepage: www.europeanurology.com Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports Vincenzo Ficarra

More information

Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape

Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape EUROPEAN UROLOGY SUPPLEMENTS 8 (2009) 787 792 available at www.sciencedirect.com journal homepage: www.europeanurology.com Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape

More information

Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment

Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment Hisanori Suzuki 1),2), Toshiro Suzuki 1),2), Osamu Ishizuka 1),2), Osamu Nishizawa 1),2),

More information

Biology of Renal Cell Cancer. Disclosures

Biology of Renal Cell Cancer. Disclosures Biology of Renal Cell Cancer Dr Joseph Ischia Uro-oncology Fellow 14-3-2012 No patents No honorariums Not on any boards Disclosures Essendon supporter 1 Renal Cell Cancer 2% of new cancers 30% have metastatic

More information

Cytoreductive nephrectomy and its role in the present-day period of targeted therapy

Cytoreductive nephrectomy and its role in the present-day period of targeted therapy 585501TAU0010.1177/1756287215585501Therapeutic Advances in UrologySH Culp review-article2015 Therapeutic Advances in Urology Review Cytoreductive nephrectomy and its role in the present-day period of targeted

More information

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan Koie et al. BMC Urology (2015) 15:32 DOI 10.1186/s12894-015-0027-4 RESEARCH ARTICLE Open Access Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution

More information

The incidence and mortality rates of renal cell carcinoma (RCC) have been rising steadily worldwide at a rate of 2% to

The incidence and mortality rates of renal cell carcinoma (RCC) have been rising steadily worldwide at a rate of 2% to Pretreatment Assessment of Tumor Enhancement on Contrast-Enhanced Computed Tomography as a Potential Predictor of Treatment Outcome in Metastatic Renal Cell Carcinoma Patients Receiving Antiangiogenic

More information

Review. Recent advances in molecularly targeted therapy in advanced renal cell carcinoma

Review. Recent advances in molecularly targeted therapy in advanced renal cell carcinoma Review Recent advances in molecularly targeted therapy in advanced renal cell carcinoma In the last few years, enhanced understanding of the biology of clear cell renal cell carcinoma has led to the development

More information

New strategies and future of target therapy in advanced kidney cancer

New strategies and future of target therapy in advanced kidney cancer New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial

More information

Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma Jose A. Karam, Brian I. Rini,* Leticia Varella, Jorge A. Garcia, Robert Dreicer, Toni K. Choueiri, Eric Jonasch, Surena

More information

Sequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC

Sequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi

More information

Emerging Biomarkers of VEGF and mtor Inhibitors in 2015

Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com

More information

Renal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford

Renal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford Renal tumours: use of immunohistochemistry & molecular pathology Dr Lisa Browning John Radcliffe Hospital Oxford Renal tumours: the use of immunohistochemistry & molecular pathology Classification of RCC

More information

RENAL EPITHELIAL TUMORS 2009: THE ROLE OF ELECTRON MICROSCOPY IN UNDERSTANDING PATHOGENESIS, DIAGNOSIS, AND CLASSIFICATION.

RENAL EPITHELIAL TUMORS 2009: THE ROLE OF ELECTRON MICROSCOPY IN UNDERSTANDING PATHOGENESIS, DIAGNOSIS, AND CLASSIFICATION. RENAL EPITHELIAL TUMORS 2009: THE ROLE OF ELECTRON MICROSCOPY IN UNDERSTANDING PATHOGENESIS, DIAGNOSIS, AND CLASSIFICATION. Guillermo A. Herrera MD Nephrocor, Tempe, Arizona Epithelial renal cell tumors

More information

E2804 The BeST Trial

E2804 The BeST Trial E2804 The BeST Trial A randomized Phase II Study of VEGF, RAF Kinase and MTOR Combination Targeted Therapy with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma Investigators Keith

More information

RENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS?

RENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS? RENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS? John C. Cheville, M.D. Mayo Clinic and Mayo Foundation Rochester, MN The majority of renal epithelial neoplasms are diagnosed on

More information

How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy

How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium sorafenib 200mg tablets (Nexavar ) (No. 321/06) Bayer Plc 6 October 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

More information

Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma

Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma Critical Reviews in Oncology/Hematology 46 (2003) S33/S39 www.elsevier.com/locate/critrevonc Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma Robert

More information

Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients

Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship

More information

Systemic therapy for advanced renal cell carcinoma

Systemic therapy for advanced renal cell carcinoma Therapeutic Advances in Medical Oncology Review Systemic therapy for advanced renal cell carcinoma James M.G. Larkin, Emma L.S. Kipps, Ceri J. Powell and Charles Swanton Ther Adv Med Oncol (2009) 1(1)

More information

Treatment Options in RCC: Past, Present and Future. Pr Stéphane Oudard, MD, PhD Georges Pompidou Hospital Paris, France

Treatment Options in RCC: Past, Present and Future. Pr Stéphane Oudard, MD, PhD Georges Pompidou Hospital Paris, France 1 Treatment Options in RCC: Past, Present and Future Pr Stéphane Oudard, MD, PhD Georges Pompidou Hospital Paris, France 2 Renal Cell Carcinoma (RCC) 208,500 new cases of kidney cancer are diagnosed this

More information

Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy

Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy Original Article - Urological Oncology Korean J Urol 5;56:5-. http://dx.doi.org/./kju.5.56..5 pissn 5-677 eissn 5-675 Interferon treatment for Japanese patients with favorable-risk metastatic renal cell

More information

TAT meeting Paris Can the tumor genome help us to better select patients for antiangiogenic therapy?

TAT meeting Paris Can the tumor genome help us to better select patients for antiangiogenic therapy? TAT meeting Paris 2011 Can the tumor genome help us to better select patients for antiangiogenic therapy? Emile E Voest Department of Medical Oncology UMC Utrecht Cancer Center Modest succes of bevacizumab

More information

Case Based Learning Program

Case Based Learning Program Case Based Learning Program The Department of Urology Glickman Urological & Kidney Institute Cleveland Clinic Case Number 5 CBULP 2010 001 Case Based Urology Learning Program Editor: Associate Editor:

More information

Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce

Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce

More information

Title. CitationCancer science, 106(5): Issue Date Doc URL. Rights(URL)

Title. CitationCancer science, 106(5): Issue Date Doc URL. Rights(URL) Title Prognosis of Japanese patients with previously untre therapy Shinohara, Nobuo; Obara, Wataru; Tatsugami, Katsunor Author(s) Sachiyo; Abe, Takashige; Oba, Koji; Naito, Seiji CitationCancer science,

More information

Fifteenth International Kidney Cancer Symposium

Fifteenth International Kidney Cancer Symposium The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee

More information

CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT

CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Cabozantinib for untreated locally advanced or metastatic renal cell carcinoma Final scope Remit/appraisal objective To appraise

More information

First-line Treatment Result Influence Second-line Regimen Selection in Targeted Therapy for Metastatic Renal Cell Carcinoma

First-line Treatment Result Influence Second-line Regimen Selection in Targeted Therapy for Metastatic Renal Cell Carcinoma First-line Treatment Result Influence Second-line Regimen Selection in Targeted Therapy for Metastatic Renal Cell Carcinoma JIAN-RI LI 1,2, CHENG-KUANG YANG 1, SHIAN-SHIANG WANG 1, CHUAN-SHU CHEN 1, KUN-YUAN

More information

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma Kim et al. BMC Urology (2016) 16:46 DOI 10.1186/s12894-016-0163-5 RESEARCH ARTICLE Open Access A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with

More information

Mechanisms of Gene Regulation and Signal! Transduction in Hypoxia!

Mechanisms of Gene Regulation and Signal! Transduction in Hypoxia! Mechanisms of Gene Regulation and Signal! Transduction in Hypoxia! Lorenz Poellinger! Dept. of Cell and Molecular Biology! Karolinska Institutet, Stockholm, Sweden! Normoxia - O 2 availability is in balance

More information

Second - Line Debate: Axitinib

Second - Line Debate: Axitinib Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.

More information

CANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /

CANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: / CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study

More information

Advanced & Metastatic Renal Cell Carcinoma

Advanced & Metastatic Renal Cell Carcinoma Advanced & Metastatic Renal Cell Carcinoma An Update G. Renzulli January 2013 1 Overview of Cancers of the Kidney 2 Global Epidemiology 3 Global Epidemiology of Kidney Cancer 4 Globally, kidney cancer

More information

Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018

Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Dr. Tzahi Neuman Dep.Of Pathology Hadassah Medical Center Jerusalem, Israel, (tneuman@hadassah.org.il) Disclosure: 1 no conflicts of

More information

Developping the next generation of studies in RCC

Developping the next generation of studies in RCC Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,

More information

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26

More information

Addenbrooke s Hospital, Cambridge, United Kingdom

Addenbrooke s Hospital, Cambridge, United Kingdom The Oncologist The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Genitourinary Cancer Cytoreductive

More information

Reference No: Author(s) Approval date: June Committee. Operational Date: July Review:

Reference No: Author(s) Approval date: June Committee. Operational Date: July Review: Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer

More information